Australian regulator warns of serious injury risk from counterfeit weight loss peptide
Source Summary
Australia's Therapeutic Goods Administration (TGA) issued a safety alert after a patient was hospitalised with a torn oesophagus following consumption of a counterfeit version of retatrutide, an unapproved experimental weight loss peptide. Retatrutide has not been approved by the TGA or overseas regulators and cannot be legally prescribed or sold in Australia. The incident highlights serious health risks associated with counterfeit pharmaceutical products.
Why it matters
The incident demonstrates that counterfeit versions of unapproved drugs can cause severe physical harm, prompting regulatory action to protect public health.
